Startseite Kongressberichte 2020 All-Virtual 62nd ASH Annual Meeting and Exposition Oral Sessions Acute Myeloid Leukemia AML - Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis III

617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Dissecting AML heterogeneity to refine treatment approaches

688 Variation in Stem Cell Driven Hierarchies Underlies Clinical Outcome and Drug Response in AML

Andy G.X. Zeng, Amanda Mitchell, Oleksandr Galkin, et al.

 

689 Integrated Stem Cell Signature and Cytomolecular Risk Determination in Pediatric Acute Myeloid Leukemia

Benjamin J. Huang, Jenny L. Smith, Rhonda E. Ries, et al.

 

690 Single-Cell Characterization of Acute Myeloid Leukemia (AML) and Its Microenvironment Identifies Signatures of Resistance to PD-1 Blockade Based Therapy

Hussein A Abbas, Dapeng Hao, Katarzyna Tomczak, et al.

 

691 Setbp1 Overexpression Acts in the Place of Class-Defining Somatic Mutations to Drive Mouse and Human FLT3-ITD-Mutant AMLs

Suruchi Pacharne, Oliver M. Dovey, Jonathan L Cooper, et al.

 

692 CC-486 Prolongs Survival for Patients with Acute Myeloid Leukemia (AML) in Remission after Intensive Chemotherapy (IC) Independent of the Presence of Measurable Residual Disease (MRD) at Study Entry: Results from the QUAZAR AML-001 Maintenance Trial

Gail J. Roboz, Farhad Ravandi, Andrew H Wei, et al.

 

693 Outcomes of TP53-Mutant Acute Myeloid Leukemia with Venetoclax and Decitabine

Kunhwa Kim, Abhishek Maiti, Tapan M. Kadia, et al.